Bio-Techne $TECH traded about 20% higher after Merck KGaA agreed to buy the company for $73 a share in cash, valuing it at about $11.3B. The offer is 36% above Bio-Techne's one-month VWAP and is expected to close in late 2026 or early 2027, subject to approvals.
A majority of SpaceX shareholders have approved a board-recommended 5-for-1 stock split, Bloomberg reported, in a move widely read as an IPO preparatory step for one of the world's most valuable private companies. The announcement follows Cerebras's blockbuster +70% IPO debut, intensifying investor anticipation for the SpaceX, OpenAI, and Anthropic public listings.
DoorDash shares rose 12% after posting Q1 2026 EPS of $0.42 vs $0.36 expected and revenue of $4.04 billion (+33% YoY). Q2 gross order value guidance of $32.4-$33.4 billion topped analyst estimates.